Open AccessCrizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors
Author(s) -
Toby N. Trahair,
Andrew J. Gifford,
Ashleigh M. Fordham,
Chelsea Mayoh,
Mitali Fadia,
Robyn Lukeis,
Andrew C. Wood,
Santosh Valvi,
Rodney A. Walker,
James Blackburn,
Erin E. Heyer,
Tim R. Mercer,
Draga Barbaric,
Glenn M. Marshall,
Karen L. MacKenzie
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00297
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , oncology , alk inhibitor , neutropenia , surgery , toxicity , lung cancer , malignant pleural effusion
Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK- positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and features associated with relapse.